Market Trends Cytokinetics started at buy by Stifel, aficamten highlightedBy admin8996erT0allJanuary 22, 2025 peterschreiber.mediaStifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock…
